FastChain®: Catalent's Solution For Made-To-Order Gene Replacement Therapy Study

A leading biopharmaceutical company developing a gene replacement therapy for a rare genetic disorder partnered with Catalent to address the complex logistical demands of a global, multi-year clinical study. Because the therapy required highly coordinated supply and rapid response once patients were identified, the sponsor needed a flexible solution capable of supporting personalized treatment across multiple regions.

Catalent implemented FastChain®, its decentralized demand-led supply model, to ensure the timely delivery of patient-specific medication kits worldwide. By aligning packaging and distribution with real-time patient enrollment, Catalent was able to quickly label, package, and dispatch personalized kits to clinical sites, minimizing delays and reducing the risk of supply shortages.

This agile approach enabled patients to begin receiving the innovative therapy promptly — often within just 14 calendar days of patient identification — while maintaining strict quality and regulatory standards. The solution helped streamline global study logistics, improve supply chain responsiveness, and support reliable access to treatment throughout the duration of the trial.